Welcome to our dedicated page for Heartbeam news (Ticker: $BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heartbeam's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heartbeam's position in the market.
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) has been granted a new patent for its novel 3D-vector electrocardiogram (VECG) platform, solidifying its position in the large global electrocardiogram patch market. This patent strengthens the company's intellectual property footprint and represents a significant step towards bringing its 12-lead extended wear patch to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
-
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) will hold a conference call on November 14, 2023, to discuss its Q3 2023 results and review recent announcements, ongoing initiatives, and anticipated 2024 milestones. The call will be hosted by CEO Branislav Vajdic, President Robert Eno, and CFO Richard Brounstein. A press release detailing the results will be issued prior to the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.73%
Tags
-
Rhea-AI Summary
Jon Hunt, a veteran in the medical device industry, has joined Implicity as its new Chief Commercial Officer (CCO), North America, to focus on business and sales strategies for the U.S. market. Implicity recently submitted for U.S. FDA clearance for a machine learning algorithm that can predict acute heart failure. The U.S. market for remote patient monitoring is expected to reach a value of more than $25 billion by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
Rhea-AI Summary
HeartBeam, Inc. appoints Richa Gujarati as Senior VP, Product, and Pooja Chatterjee as VP, Clinical. Gujarati will handle product roadmap and go-to-market strategy, while Chatterjee will lead the clinical pipeline for FDA clearances. Their expertise will support the commercialization of HeartBeam's ambulatory VECG products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
-
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) strengthens its Board of Directors and IP position, publishes a peer-reviewed article, and reports Q2 2023 operational and financial results. The company closed $26.5 million in financings, announced key additions to the board, and appointed a new Vice President of Regulatory Affairs. They also submitted a 510(k) application to the FDA for their HeartBeam AIMIGo™ System. Q2 2023 financial results show a net loss of $3.2 million and cash, cash equivalents, and short-term investments totaling approximately $21.3 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
Rhea-AI Summary
HeartBeam, Inc. has appointed Deborah Castillo, PhD, as Vice President of Regulatory Affairs. Castillo brings extensive experience in regulatory affairs and quality assurance for medical devices and diagnostics, with a focus on cardiovascular diseases and neuroscience. She will lead HeartBeam's regulatory affairs function and support the company's clinical development and commercialization efforts for its novel HeartBeam AIMIGo™ Platform Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
HeartBeam, Inc. (NASDAQ: BEAT) announces the appointment of Michael R. Jaff, DO, a renowned Vascular Physician and Researcher, to its board of directors. Dr. Jaff brings extensive clinical and industry experience, having held key positions at Boston Scientific Corporation and Harvard Medical School. This move strengthens HeartBeam's board with Dr. Jaff's expertise in vascular medicine and innovation, aligning with the company's focus on developing advanced cardiac technology, including the 3D-vector electrocardiogram (VECG) platform for home use. The appointment reflects HeartBeam's commitment to leveraging top talent for advancing its cardiac technology solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Heartbeam, Inc.
Nasdaq:BEAT
BEAT Rankings
BEAT Stock Data
51.73M
19.29M
28.17%
8.8%
0.61%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SANTA CLARA
About BEAT
heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.